BiotechTube

Venglustat (GZ402671) + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Mar 11, 2022 → Jan 4, 2027

NCT ID
NCT05206773

About Venglustat (GZ402671) + Placebo

Venglustat (GZ402671) + Placebo is a phase 3 stage product being developed by Sanofi for Fabry Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05206773. Target conditions include Fabry Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05206773Phase 3Active

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
72
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
51
agalsidase betaSanofiApproved
84
TropicamideSanofiPre-clinical
22
Fabrazyme (agalsidase beta)SanofiApproved
84
agalsidase betaSanofiApproved
84
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
84
Gabapentin + placeboSanofiPhase 2
51
Agalsidase betaSanofiApproved
84
GZ/SAR402671SanofiPhase 2
51
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
84
Fabrazyme (agalsidase beta)SanofiPhase 3
76
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + MigalastatSanofiPhase 3
76
IohexolSanofiPhase 1
32
GZ/SAR402671SanofiPhase 2
51
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Agalsidase betaSanofiApproved
84
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
84
Agalsidase beta + Agalsidase betaSanofiPhase 3
76

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84